go-v.orgdoi

Outcomes of novel trials for cancer cachexia

Rony Dev, Egidio Del Fabbro, Eduardo D Bruera · Clinical Investigation · 2014

  • DOI 10.4155/cli.14.9
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2014

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2014

Abstract

Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle and fat, reduced quality of life and decreased survival. Unlike starvation, weight loss cannot be fully reversed by increasing caloric intake. Interventions, such as nutritional counseling or currently available appetite stimulants such as megestrol acetate have limited benefits. Recently, there has been an increase in the understanding of the pathophysiology contributing to weight loss in patients with cancer. Clinical trials of various pharmacological therapies targeting the underlying pathophysiological derangements contributing to cancer cachexia are underway.

A personalized approach may be needed for managing patients with anorexia–cachexia syndrome in conjunction with the best supportive care. The following narrative review will highlight novel therapies being investigated for the treatment of cancer cachexia, which can be used as a single-agent or combined in multimodal therapy.

Open the resolved locator · 10.4155/cli.14.9

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:30 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.14.9
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.